RTW Investments LP Raises Holdings in uniQure (NASDAQ:QURE)

RTW Investments LP lifted its position in uniQure (NASDAQ:QURE - Free Report) by 8,936.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 903,625 shares of the biotechnology company's stock after purchasing an additional 893,625 shares during the period. RTW Investments LP owned about 1.85% of uniQure worth $15,958,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Invesco Ltd. increased its stake in shares of uniQure by 453.2% in the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock worth $10,836,000 after acquiring an additional 502,684 shares in the last quarter. Sanders Morris Harris LLC increased its position in uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company's stock valued at $1,803,000 after acquiring an additional 34,034 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of uniQure in the fourth quarter worth approximately $320,000. Palumbo Wealth Management LLC purchased a new position in shares of uniQure during the 4th quarter worth $437,000. Finally, Raymond James Financial Inc. purchased a new position in shares of uniQure during the 4th quarter valued at about $1,951,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure Price Performance

NASDAQ QURE traded up $1.01 during trading hours on Monday, reaching $14.71. The company's stock had a trading volume of 1,398,654 shares, compared to its average volume of 1,881,488. The firm has a market capitalization of $805.75 million, a price-to-earnings ratio of -2.97 and a beta of 0.10. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The company's 50-day moving average is $12.31 and its two-hundred day moving average is $12.37.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.25. The company had revenue of $1.57 million for the quarter, compared to analysts' expectations of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, equities analysts predict that uniQure will post -3.75 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Chardan Capital reiterated a "buy" rating and set a $38.00 price objective on shares of uniQure in a research report on Monday, May 12th. StockNews.com raised uniQure to a "sell" rating in a research note on Tuesday, March 11th. Royal Bank of Canada restated an "outperform" rating and issued a $24.00 price objective on shares of uniQure in a report on Tuesday, January 21st. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price objective on shares of uniQure in a research report on Monday, April 21st. Finally, Wells Fargo & Company lowered their price objective on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $37.82.

Insider Activity

In other news, CFO Christian Klemt sold 10,438 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $107,407.02. Following the transaction, the chief financial officer now owns 217,730 shares of the company's stock, valued at approximately $2,240,441.70. The trade was a 4.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 26,727 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $285,978.90. Following the sale, the chief executive officer now owns 571,188 shares of the company's stock, valued at approximately $6,111,711.60. The trade was a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,830 shares of company stock worth $961,401 over the last three months. Insiders own 4.74% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.